{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:26:30Z","timestamp":1768897590622,"version":"3.49.0"},"reference-count":61,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"unspecified","delay-in-days":15278,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1976,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A rational approach to the use of monoamine oxidase inhibitors (MAOIs) is outlined. Patients suitable for treatment cannot be classified adequately using conventional diagnostic labels. They include those with primary symptoms of hypochondriasis, agoraphobia and social phobias, irritability, somatic anxiety and anergia; those with primary depressed mood, guilt, ideas of reference and personality disorders seldom respond. There is great variation in the interval between the first administration of these drugs and clinical response, and this may account for the inconsistencies in published trials. The type of drug and its dose may affect rate of response, as may biochemical factors, including acetylator and monoamine oxidase status. To obtain maximum benefit, a course of therapy with MAOIs should last for several months.<\/jats:p>","DOI":"10.1192\/bjp.128.4.354","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T22:35:43Z","timestamp":1218580543000},"page":"354-360","source":"Crossref","is-referenced-by-count":87,"title":["Towards Rational Therapy with Monoamine Oxidase Inhibitors"],"prefix":"10.1192","volume":"128","author":[{"given":"Peter","family":"Tyrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,29]]},"reference":[{"key":"S0007125000092783_ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5270.9"},{"key":"S0007125000092783_ref4","article-title":"Adverse reactions to local anaesthetic\/vasoconstrictor preparations","volume":"133","author":"Boakes","year":"1972","journal-title":"British Dental Journal"},{"key":"S0007125000092783_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.01750330045008"},{"key":"S0007125000092783_ref25","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.120.8.808"},{"key":"S0007125000092783_ref6","article-title":"Interaction between Clonidine and desipramine in man","volume":"i","author":"Briant","year":"1973","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref14","doi-asserted-by":"publisher","DOI":"10.1038\/2201330a0"},{"key":"S0007125000092783_ref47","article-title":"Biological half-life of chlordiazepoxide and its metabolite, demoxepam, in man","volume":"60","author":"Schwartz","year":"1971","journal-title":"Journal of Pharmaceutical Science"},{"key":"S0007125000092783_ref57","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.127.2.163"},{"key":"S0007125000092783_ref39","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.121.2.147"},{"key":"S0007125000092783_ref2","article-title":"Hypertensive crisis due to monoamine oxidase inhibitors","volume":"ii","author":"Blackwell","year":"1963","journal-title":"Lancet"},{"key":"S0007125000092783_ref32","article-title":"Differentiation of two genetically specific types of depression by the response to antidepressants","volume":"ii","author":"Pare","year":"1962","journal-title":"Lancet"},{"key":"S0007125000092783_ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5270.6"},{"key":"S0007125000092783_ref30","unstructured":"Mountjoy C. Q. & Roth M. (1974) A double-blind clinical trial of phenelzine in anxiety states, reactive depression and agoraphobia. Paper given at 9th Congress of C.I.N.P., July 1974."},{"key":"S0007125000092783_ref37","article-title":"A controlled trial of phenelzine (\u2018Nardil\u2019) in the treatment of severe depressive illness","volume":"107","author":"Rees","year":"1961","journal-title":"Journal of Mental Science"},{"key":"S0007125000092783_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(70)90078-7"},{"key":"S0007125000092783_ref58","article-title":"Effect of iproniazid in depressive syndromes","volume":"i","author":"West","year":"1959","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref52","doi-asserted-by":"publisher","DOI":"10.1177\/070674377301800106"},{"key":"S0007125000092783_ref31","article-title":"Side-effects and toxic effects of antidepressants","volume":"57","author":"Pare","year":"1964","journal-title":"Proceedings of Royal Society of Medicine"},{"key":"S0007125000092783_ref27","doi-asserted-by":"publisher","DOI":"10.1007\/BF00421708"},{"key":"S0007125000092783_ref29","article-title":"Clinical trial of the treatment of depressive illness: report by MRC Clinical Psychiatry Committee","volume":"i","year":"1965","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref61","doi-asserted-by":"publisher","DOI":"10.1038\/236225b0"},{"key":"S0007125000092783_ref40","article-title":"Is there an increase in monoamine-oxidase activity in depressive illness?","volume":"i","author":"Sandler","year":"1975","journal-title":"Lancet"},{"key":"S0007125000092783_ref18","first-page":"151","volume-title":"The Pharmacological Basis of Therapeutics","author":"Jarvik","year":"1970"},{"key":"S0007125000092783_ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1974.tb00198.x"},{"key":"S0007125000092783_ref8","article-title":"Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure","volume":"ii","author":"Elis","year":"1967","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.119.551.399"},{"key":"S0007125000092783_ref59","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1971.01750080049007"},{"key":"S0007125000092783_ref10","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.120.10.935"},{"key":"S0007125000092783_ref11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.121.2.162"},{"key":"S0007125000092783_ref13","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.106.445.1432"},{"key":"S0007125000092783_ref20","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.123.1.63"},{"key":"S0007125000092783_ref16","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.106.443.704"},{"key":"S0007125000092783_ref21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.124.4.352"},{"key":"S0007125000092783_ref5","article-title":"Interaction between sympathomimetic amines and antidepressant agents in man","volume":"i","author":"Boakes","year":"1973","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref22","doi-asserted-by":"crossref","DOI":"10.5694\/j.1326-5377.1962.tb26410.x","article-title":"Phenelzine treatment of Roth's calamity syndrome","volume":"1","author":"King","year":"1962","journal-title":"Medical Journal of Australia"},{"key":"S0007125000092783_ref56","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422146"},{"key":"S0007125000092783_ref23","doi-asserted-by":"publisher","DOI":"10.1007\/BF02193476"},{"key":"S0007125000092783_ref24","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.112.488.651"},{"key":"S0007125000092783_ref26","doi-asserted-by":"publisher","DOI":"10.1007\/BF00402639"},{"key":"S0007125000092783_ref54","article-title":"Are monoamine oxidase inhibitors antidepressants?","volume":"66","author":"Tyrer","year":"1973","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"S0007125000092783_ref28","article-title":"Treatment of obsessional illness and phobic anxiety states with clomipramine","volume":"119","author":"Marshall","year":"1972","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000092783_ref33","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.118.544.275"},{"key":"S0007125000092783_ref34","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.115.525.937"},{"key":"S0007125000092783_ref35","article-title":"Withdrawal symptoms after stopping phenelzine?","volume":"ii","author":"Pitt","year":"1974","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref36","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760070050008"},{"key":"S0007125000092783_ref41","article-title":"Psychiatric treatment in general teaching hospitals: a plea for a mechanistic approach","volume":"ii","author":"Sargant","year":"1966","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref42","unstructured":"Sargant W. (1969) Physical treatments of anxiety. In Studies of Anxiety (ed. Lader M. H. ), pp. 1\u20136. British Journal of Psychiatry Special Publication No. 3."},{"key":"S0007125000092783_ref44","volume-title":"Physical Methods of Treatment in Psychiatry","author":"Sargant","year":"1963"},{"key":"S0007125000092783_ref46","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1971.01750120025005"},{"key":"S0007125000092783_ref49","article-title":"Interaction between monoamine oxidase inhibitors and other substances","volume":"58","author":"Sj\u00f6qvist","year":"1965","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"S0007125000092783_ref38","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1973.04200030093015"},{"key":"S0007125000092783_ref50","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.121.2.238"},{"key":"S0007125000092783_ref51","first-page":"16","article-title":"Mechanism of antidepressant efficacy of monoamine oxidase inhibitors: inhibition of monoamine oxidase or of catecholamine response","volume":"10","author":"Snyder","year":"1974","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000092783_ref53","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(68)90364-0"},{"key":"S0007125000092783_ref55","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700046419"},{"key":"S0007125000092783_ref60","doi-asserted-by":"publisher","DOI":"10.1038\/223626a0"},{"key":"S0007125000092783_ref17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.109.461.536"},{"key":"S0007125000092783_ref48","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.124.3.265"},{"key":"S0007125000092783_ref19","article-title":"Acetylator status and response to phenelzine in depressed patients","volume":"i","author":"Johnstone","year":"1973","journal-title":"Lancet"},{"key":"S0007125000092783_ref45","article-title":"Simplified method for determining acetylator phenotype","volume":"iii","author":"Schr\u00f6der","year":"1972","journal-title":"British Medical Journal"},{"key":"S0007125000092783_ref15","volume-title":"Clinical Use of Psychotherapeutic Drugs","author":"Hollister","year":"1973"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000092783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T16:25:56Z","timestamp":1588868756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000092783\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1976,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1976,4]]}},"alternative-id":["S0007125000092783"],"URL":"https:\/\/doi.org\/10.1192\/bjp.128.4.354","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1976,4]]}}}